Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Other Non Operating Income (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Other Non Operating Income for 13 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 72.55% to -$5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$13.8 million through Sep 2025, down 77.06% year-over-year, with the annual reading at -$12.6 million for FY2024, 330.94% down from the prior year.
  • Other Non Operating Income hit -$5.2 million in Q4 2025 for Coherus Oncology, down from $2.1 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $10.0 million in Q4 2022 to a low of -$19.0 million in Q4 2024.
  • Historically, Other Non Operating Income has averaged -$484150.0 across 5 years, with a median of $315000.0 in 2022.
  • Biggest five-year swings in Other Non Operating Income: soared 5300.0% in 2023 and later crashed 14667.44% in 2024.
  • Year by year, Other Non Operating Income stood at -$385000.0 in 2021, then skyrocketed by 2708.83% to $10.0 million in 2022, then tumbled by 101.28% to -$129000.0 in 2023, then plummeted by 14667.44% to -$19.0 million in 2024, then skyrocketed by 72.55% to -$5.2 million in 2025.
  • Business Quant data shows Other Non Operating Income for CHRS at -$5.2 million in Q4 2025, $2.1 million in Q3 2025, and $2.9 million in Q2 2025.